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Abstract 
Meropenem–vaborbactam is a carbapenem/cyclic boronic acid β-lactamase inhibitor 
combination primarily active against Gram-negative bacilli, including those harboring class A 
serine carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC). A Clinical and 
Laboratory Standards Institute M23-A4 (Tier 2) quality control study established broth 
microdilution and disk diffusion ranges for reference strains. Two KPC-producing K. 
pneumoniae ATCC strains are recommended for quality control testing. 
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1. Introduction 
The significance of multidrug-resistant Enterobacteriaceae to clinical medicine has been well 
documented, particularly in terms of disease incidence rates and association with poor clinical 
outcomes (Thaden et al., 2017). Carbapenem-resistant Enterobacteriaceae (CRE) are viewed 
as an urgent threat in this context (CDC, 2013) because rates of these infections have 
increased globally (Sievert et al., 2013, van Duijn et al., 2011), invasive infections with CRE 
are associated with significant mortality (Tzouvelekis et al., 2012), and options to treat these 
organisms have become limited (Thaden et al., 2017). Vaborbactam (formerly RPX7009) is a 
cyclic boronic acid β-lactamase inhibitor designed to inactivate class A serine 
carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC) (Hecker et al., 2015). 
Castanheira et al. (2016) reported that vaborbactam restored meropenem activity against a 
majority of KPC-producing isolates (optimally at a concentration of 8 μg/mL). This agent was 
well tolerated in a phase 1 healthy-volunteer study (Griffith et al., 2016, Wenzler et al., 2015). 
A fixed-dose meropenem–vaborbactam product has completed phase 3 clinical trials for the 
treatment of complicated urinary tract infection (including acute pyelonephritis) and serious 
infection due to CRE (ClincalTrials.gov, 2016, ClincalTrials.gov, 2017). The formulation is now 
FDA-approved for treatment of adult patients with complicated urinary tract infection, including 
pyelonephritis, caused by selected Enterobacteriaceae. 
This investigation established broth microdilution and disk diffusion meropenem and 
meropenem–vaborbactam quality control (QC) ranges for Clinical and Laboratory Standards 
Institute (CLSI) reference strains of Gram-positive cocci and Gram-negative bacilli. The 
addition of two KPC-producing K. pneumoniae reference strains [ATCC BAA-1705 (KPC-2, 
SHV) and ATCC BAA-2814 (KPC-3, SHV-11, TEM-1)] allows for QC of meropenem both alone 
and in combination with fixed concentration vaborbactam using different parts of the 
susceptibility dilution range. Meropenem–vaborbactam (VABOMERE™) recently received FDA 
approval for the treatment of complicated urinary tract infection (VABOMERE™, 2017). Broth 
microdilution and disk diffusion QC ranges for meropenem–vaborbactam will assist both 
clinical and reference laboratories in generating accurate susceptibility testing results in clinical 
microbiology practice. 
2. Materials and Methods 
Quality control investigations were designed using CLSI M23-A4 guidelines (CLSI, 2016) for 
Tier 2 studies. Frozen-form broth microdilution susceptibility panels containing meropenem–
vaborbactam (testing range 0.004/8–8/8 μg/mL) and meropenem (testing range 0.125–
256 μg/mL) were prepared at TREK Diagnostics/ThermoFisher Scientific (Oakwood Village, 
OH). Initial testing included Escherichia coli ATCC 25922 and ATCC 35218, K. pneumoniae 
ATCC 700603, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 
29213 using Mueller–Hinton broth (MHB) acquired from Becton Dickinson (BD; Sparks, MD; lot 
2089488), Difco (Detroit, MI; lot 2080123), and Oxoid (Hampshire, United Kingdom; lot 
1119455). Subsequent testing included KPC-producing reference strains (K. pneumoniae 
ATCC BAA-1705 and ATCC BAA-2814) and MHB lots obtained from BD (4293655), Difco 
(4196913), and Oxoid (1433705). Meropenem and vaborbactam powders were provided by 
The Medicines Company (Parsippany, NJ). All susceptibility testing and the majority of QC 
range determinations followed CLSI guidelines (CLSI, 2015, CLSI, 2016). In certain scenarios, 
these determinations were supplemented with data derived from the RangeFinder statistical 
program (Turnidge and Bordash, 2007), which utilizes mean, median, and modal values to 
identify outliers. 
Meropenem–vaborbactam and meropenem MIC values were obtained over a minimum of 3 
days by 8 independent laboratories, generating 1 MIC value per strain/medium lot for 10 
replicates (240 total MIC values per reference strain and test compound). Inoculum 
assessment yielded mean colony counts ranging from 2.9 × 105 (K. pneumoniae ATCC 
700603) to 4.5 × 105 CFU/mL (P. aeruginosa ATCC 27853). Internal quality assurance for 
frozen panels included analysis of P. aeruginosa ATCC 27853 against meropenem (nine 
replicates per laboratory) and piperacillin–tazobactam (testing range 0.06/4–32/4 μg/mL; six 
replicates per laboratory). 
For disk diffusion testing, individual lots of meropenem–vaborbactam disks (20/10 μg) were 
obtained from Bio-Rad Laboratories (Hercules, CA; lot 5H0011) and the MAST Group (Bootle, 
Merseyside, United Kingdom; lot 357368). Mueller–Hinton agar (MHA) was obtained from 
Hardy Diagnostics (Santa Maria, CA; lot H11-15302), ThermoFisher (Lenexa, Ks; lot 766782), 
and BBL (Sparks, MD; lot 5287893). Susceptibility testing and disk diffusion QC range 
determinations followed CLSI guidelines (CLSI, 2015, CLSI, 2016). Meropenem–vaborbactam 
disk zone diameters against E. coli ATCC 25922; K. pneumoniae ATCC 700603, ATCC BAA-
1705, and ATCC BAA-2814; P. aeruginosa ATCC 27853; and S. aureus ATCC 25923 were 
obtained by 7 laboratories over a minimum interval of 3 days, generating 1 zone diameter 
value per reference strain/disk lot/medium lot for 10 replicates (420 total zone diameter values 
per reference strain and test compound). Internal quality assurance included analysis of 
selected strains against 10 μg meropenem (BD lot 5147624) and 100/10 μg piperacillin–
tazobactam disks (BD lot 5111769; 30 replicates per laboratory). 
3. Results and Discussion 
Broth microdilution quality assurance testing demonstrated that 98.8% of meropenem and 
100.0% of piperacillin–tazobactam MIC values for P. aeruginosa ATCC 27853 were within QC 
ranges published in the CLSI M100-S27 (CLSI, 2017) document (data not shown). Three log2-
dilution meropenem–vaborbactam QC ranges were characterized for S. aureus ATCC 29213 
(0.03/8–0.12/8 μg/mL) and K. pneumoniae ATCC 700603 (0.015/8–0.06/8 μg/mL), accounting 
for ≥97.1% of all MIC values (Table 1). On the basis of CLSI M23-A4 criteria and bimodal MIC 
distributions, four log2-dilution meropenem–vaborbactam QC ranges were calculated for E. coli 
ATCC 25922 (0.008/8–0.06/8 μg/mL), E. coli ATCC 35218 (0.008/8–0.06/8 μg/mL), and P. 
aeruginosa ATCC 27853 (0.12/8–1/8 μg/mL), encompassing 100.0% of all MIC values. 
Susceptibility shoulders were noted within these three strains representing 72.0%, 60.0%, and 
65.3% of the modal meropenem–vaborbactam MIC values, respectively. With respect to E. coli 
ATCC 35218, RangeFinder calculated a three log2-dilution QC range of 0.015/8–0.06/8 μg/mL, 
encompassing 98.3% of meropenem–vaborbactam MIC values. 
Table 1. CLSI-approved broth microdilution and disk diffusion zone diameter quality control 
ranges for meropenem–vaborbactam and meropenem. 
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a --, no proposed range. 
b Previously approved CLSI QC range for meropenem. 
c QC range established using meropenem zone diameter data from one manufacturer. 
K. pneumoniae ATCC BAA-1705 and ATCC BAA-2814 were investigated as potential QC 
reference strains as the currently available strains could not adequately QC the activity of the 
meropenem–vaborbactam combination over meropenem alone. In addition, K. pneumoniae 
ATCC BAA-1705 and ATCC BAA-2814 allow for the QC of different portions of the 
meropenem–vaborbactam QC range. With respect to meropenem–vaborbactam, CLSI M23-
A4 criteria and RangeFinder both calculated a three log2-dilution QC range of 0.12/8–
0.5/8 μg/mL for K. pneumoniae ATCC 2814 (Fig. 1), encompassing 98.3% of MIC values. For 
K. pneumoniae ATCC BAA-1705, the meropenem–vaborbactam modal MIC value of 
0.015/8 μg/mL demonstrated a 67.7% shoulder at 0.03 μg/mL, supporting a four log2-dilution 
QC range of 0.008/8–0.06/8 μg/mL (Fig. 1). These data were corroborated by RangeFinder 
and included 99.6% of meropenem–vaborbactam MIC values. Individual MHB lots 
incorporated into meropenem–vaborbactam QC range determination resulted in between 
88.8% and 96.3% of K. pneumoniae ATCC BAA-1705 MIC values recorded at 0.015/8 or 
0.03/8 μg/mL. Similarly, analysis of K. pneumoniae ATCC BAA-2814 meropenem–
vaborbactam data revealed that, irrespective of MHB lot, 97.5% to 98.8% of MIC values fell 
between 0.12/8 and 0.5/8 μg/mL. 
 
Fig. 1. CLSI-approved broth microdilution meropenem–vaborbactam (fixed 8 μg/mL) MIC distributions by medium 
lot for K. pneumoniae ATCC BAA-1705 (KPC-2) and K. pneumoniae ATCC BAA-2814 (KPC-3). Medium lot A is 
Becton Dickinson, medium lot B is Difco, and medium lot C is Oxoid. 
A bimodal distribution of meropenem MIC values against K. pneumoniae ATCC BAA-2814 was 
observed (Fig. 2), indicating a four log2-dilution QC range of 32–256 μg/mL that included 
100.0% of all MIC values. With respect to K. pneumoniae ATCC BAA-1705, a four log2-dilution 
QC range of 8–64 μg/mL including 95.8% of all meropenem MIC values was proposed using 
CLSI M23-A4 criteria and RangeFinder results (Fig. 2). 
 
Fig. 2. CLSI approved broth microdilution meropenem MIC distributions by medium lot for K. pneumoniae ATCC 
BAA-1705 (KPC-2) and K. pneumoniae ATCC BAA-2814 (KPC-3). Medium lot A is Becton Dickinson, medium lot 
B is Difco, and medium lot C is Oxoid. 
Disk diffusion quality assurance demonstrated 99.8% and 100.0% of meropenem and 
piperacillin-tazobactam zone diameters, respectively, within CLSI-published QC ranges (CLSI, 
2017). The results of two laboratories were identified by RangeFinder as statistical outliers for 
their modal meropenem zone diameter values for S. aureus ATCC 25923. One laboratory was 
identified by RangeFinder as a statistical outlier for the modal meropenem MIC value against 
P. aeruginosa ATCC 27853, and another laboratory was identified as a statistical outlier for the 
meropenem MIC value against K. pneumoniae ATCC 700603. The results of two laboratories 
were based on modal meropenem–vaborbactam zone diameter outliers for S. aureus ATCC 
25923. The aforementioned laboratories were not excluded from subsequent analysis, as the 
mean and median zone diameter values (as calculated by RangeFinder) were within 
acceptable limits. Meropenem–vaborbactam 20/10-μg disks produced by Bio-Rad yielded 
slightly larger zone diameters (geometric mean difference between 0.1 and 1 mm) than disks 
produced by MAST. 
With respect to a 20/10-μg meropenem–vaborbactam disk, zone diameter QC ranges of 32–
38 mm for S. aureus ATCC 25923 (encompassing 97.6% of zone diameter values), 31–37 mm 
for E. coli ATCC 25922 (including 99.0% of zone diameter values), and 29–35 mm for both K. 
pneumoniae ATCC 700603 and P. aeruginosa ATCC 27853 (99.3% of zone diameter values 
inclusive in both instances) were proposed (Table 1). These zone diameter values were 
derived from calculation of the 95% confidence interval around the mean (CLSI, 2016). 
RangeFinder corroborated all findings, with the exception of a larger proposed range for S. 
aureus ATCC 25923 (31–39 mm) that encompassed 99.8% of zone diameter values. For a 10-
μg meropenem control disk, zone diameter QC ranges of 29–37 mm for S. aureus ATCC 
25923 and 27–33 mm for P. aeruginosa ATCC 27853 included 100.0% and 99.5% of all zone 
diameter values, respectively. Of note, the previously approved meropenem disk diffusion QC 
range of 28–34 mm for E. coli ATCC 25922 (encompassing 100.0% of zone diameter values; 
Table 1) was revised to 28–35 mm based on the outcome of this multilaboratory QC study 
(CLSI, 2017). 
In further studies to identify relevant carbapenem/β-lactamase inhibitor QC strains, a 
meropenem–vaborbactam disk diffusion QC range of 21–27 mm for K. pneumoniae ATCC 
BAA-1705 was determined (Fig. 3). Alternatively, a RangeFinder zone diameter QC range of 
22–27 mm included 100.0% of results. No skewing was observed with respect to lot of MHA 
used. 
 
Fig. 3. CLSI-approved disk diffusion meropenem–vaborbactam (20/10 μg) zone diameter distributions by medium 
lot for K. pneumoniae ATCC BAA-1705 (KPC-2) and K. pneumoniae ATCC BAA-2814 (KPC-3). Medium lot A is 
Remel, medium lot B is Hardy Diagnostics, and medium lot C is BBL. 
A CLSI-derived meropenem zone diameter range of 12–18 mm included 96.2% of all zone 
diameter values, while a zone diameter QC range of 11–18 mm, as determined by 
RangeFinder (Fig. 4), captured 99.5% of zone diameter values. However, this meropenem 
analysis was limited by single-lot disk testing. For K. pneumoniae ATCC BAA-2814, a CLSI 
M23-A4 zone diameter QC range of 16–20 mm for meropenem–vaborbactam (20/10 μg) 
included all zone diameter values (Fig. 3). All K. pneumoniae ATCC BAA-2814 replicates 
demonstrated no meropenem inhibition zone (6 mm; single-lot disk testing), confirming the 
carbapenem-resistant nature of this strain. These data, as well as MIC findings (Fig. 1, Fig. 2), 
ascribe value to both K. pneumoniae ATCC BAA-1705 and ATCC BAA-2814 as QC reference 
strains confirming both the antibacterial activity of meropenem and demonstrating the β-
lactamase inhibitor activity of vaborbactam. 
 
Fig. 4. CLSI-approved disk diffusion meropenem (10 μg) zone diameter distributions by medium lot for K. 
pneumoniae ATCC BAA-1705 (KPC-2) and K. pneumoniae ATCC BAA-2814 (KPC-3). Medium lot A is Remel, 
medium lot B is Hardy Diagnostics, and medium lot C is BBL. 
The CLSI Subcommittee on Antimicrobial Susceptibility Testing approved the proposed 
meropenem and meropenem–vaborbactam MIC QC ranges (Table 1) for E. coli ATCC 25922 
and 35218, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, and S. aureus ATCC 
29213 in January 2015. Disk diffusion QC ranges for E. coli ATCC 25922; K. pneumoniae 
ATCC 700603, ATCC BAA-1705, and ATCC BAA-2814; P. aeruginosa ATCC 27853; and S. 
aureus ATCC 25923 were approved in June 2016. MIC QC ranges for K. pneumoniae ATCC 
BAA-1705 and ATCC BAA-2814 were approved in January 2017 after publication of the CLSI 
M100-S27 document. Values listed in Table 1 also reflect those listed in the FDA-approved 
formulation of meropenem–vaborbactam (VABOMERE™, 2017), with the exception of the 
revised MIC QC range for K. pneumoniae ATCC BAA-1705 and the newly approved MIC QC 
range for K. pneumoniae ATCC BAA-2814. K. pneumoniae ATCC BAA-1705 and/or K. 
pneumoniae ATCC BAA-2814 should be used as QC reference strains when evaluating the 
activity of meropenem–vaborbactam combinations as they provide QC on both the 
meropenem and vaborbactam components of the antimicrobial combination. 
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